Immune checkpoint inhibitors are now an integral part of cancer treatment, and cutaneous side effects are common. We report the case of a 40-year-old woman who developed purpura pigmentosa progressiva (PPP) in temporal association with pembrolizumab. This case... ...

请注册登录后继续浏览